MVM Life Science Partners today announced the closing of a $233 million healthcare fund, MVM IV. The fund is MVM’s fourth and largest raised to date.

MVM IV is investing in medical companies, principally in Europe and the United States. The fund invests broadly across the healthcare field including in technologies, therapeutics, medical devices and healthcare IT and across all stages of development from early-stage private deals to quoted companies. Investment size will generally range from $15 million up to $30 million per portfolio company.

“We have had a very positive response from investors and we are delighted with the group of investors we have been able to attract,” said Dr Stephen Reeders, Managing Partner. “We believe the fund raising was helped by several factors including MVM’s compelling investment strategy, extensive track record, the strength of the team and our transatlantic presence with offices in London and Boston.”


MVM is a long-established investment firm dedicated to the healthcare sector on both sides of the Atlantic. The firm invests in healthcare businesses across all stages of development, from early-stage to public companies. In aggregate, MVM has raised four funds totaling over $700 million. MVM has offices in London and Boston.

Historic investments

Successful investments have included Domantis, Heptares, Preglem, Momenta, Vascular Pathways, Beacon Endoscopic, Cara Therapeutics, Aegerion and HBI. For a full list of MVM’s portfolio companies please visit the website.

This press release, together with any information or documents accompanying it, is issued by MVM Life Science Partners LLP, which is authorised and regulated in the UK by the Financial Conduct Authority, and is intended to be communicated only to persons engaged in or employed by, or directing or managing, a business that involves dissemination through publication of information concerning investments, in accordance with Article 20(2)(a) and (b) of the Financial Services and Markets Act 2000 (Promotion of Collective Investment Schemes)(Exemptions) Order 2001.

This document does not constitute an offer or invitation to subscribe or purchase limited partnership interests. Any investment in MVM IV LP will be made solely on the basis of the private placement memorandum issued in connection therewith and the limited partnership agreement and associated documentation.

MVM Life Science Partners LLP
Dr Stephen Reeders
Managing Partner

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Discover our Briefings.